Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Cost of Revenue (2018 - 2024)

Abvc Biopharma (ABVC) has disclosed Cost of Revenue for 8 consecutive years, with -$831900.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue changed N/A year-over-year to -$831900.0, compared with a TTM value of -$831414.0 through Dec 2025, down 109066.45%, and an annual FY2024 reading of $763.0, down 99.75% over the prior year.
  • Cost of Revenue was -$831900.0 for Q4 2025 at Abvc Biopharma, down from $296.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $265411.0 in Q4 2022 and bottomed at -$831900.0 in Q4 2025.
  • Average Cost of Revenue over 5 years is -$14849.9, with a median of $2349.0 recorded in 2021.
  • The sharpest move saw Cost of Revenue soared 9372.2% in 2022, then crashed 99.74% in 2024.
  • Year by year, Cost of Revenue stood at $2802.0 in 2021, then skyrocketed by 9372.2% to $265411.0 in 2022, then plummeted by 47.55% to $139206.0 in 2023, then tumbled by 99.79% to $296.0 in 2024, then crashed by 281147.3% to -$831900.0 in 2025.
  • Business Quant data shows Cost of Revenue for ABVC at -$831900.0 in Q4 2025, $296.0 in Q3 2024, and $190.0 in Q2 2024.